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Background: Stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer (NSCLC) has led to promising
local control and overall survival for fractionation schemes with increasingly high fractional doses. A point has
however been reached where the number of fractions used might be too low to allow efficient local inter-fraction
reoxygenation of the hypoxic cells residing in the tumour. It was therefore the purpose of this study to investigate
the impact of hypoxia and extreme hypofractionation on the tumour control probability (TCP) from SBRT.
Methods: A three-dimensional model of tumour oxygenation able to simulate oxygenation changes on the
microscale was used. The TCP was determined for clinically relevant SBRT fractionation schedules of 1, 3 and 5
fractions assuming either static tumour oxygenation or that the oxygenation changes locally between fractions due
to fast reoxygenation of acute hypoxia without an overall reduction in chronic hypoxia.
Results: For the schedules applying three or five fractions the doses required to achieve satisfying levels of TCP
were considerably lower when local oxygenation changes were assumed compared to the case of static
oxygenation; a decrease in D50 of 17.7 Gy was observed for a five-fractions schedule applied to a 20% hypoxic
tumour when fast reoxygenation was modelled. Assuming local oxygenation changes, the total doses required for
a tumor control probability of 50% were of similar size for one, three and five fractions.
Conclusions: Although attractive from a practical point of view, extreme hypofractionation using just one single
fraction may result in impaired local control of hypoxic tumours, as it eliminates the possibility for any kind of
reoxygenation.
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The use of stereotactic body radiation therapy (SBRT) has
continuously grown and proven highly successful in the
treatment of lung cancer [1-9] since the first treatments of
extra-cranial malignancies employing few high-dose frac-
tions performed by Blomgren and Lax in the 1990s [1,2].
As treatments delivered in fewer fractions are more advan-
tageous from both economical and practical points of view,
there is a tendency towards extreme hypofractionation in* Correspondence: emely.lindblom@ki.se
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unless otherwise stated.SBRT. The high precision allowed by the use of a stereo-
tactic frame to fixate the patient or, more recently, image-
guided frameless techniques has enabled an escalation of
the fractional dose. However, the impact of extreme hy-
pofractionation on the treatment outcome must also be
evaluated from a radiobiological point of view as such
schedules may pose a challenge to the radiobiological ra-
tionale behind fractionation summarized by the so-called 5
R’s of radiobiology. A reduced number of fractions implies
a shorter treatment time, but also requires a higher dose
per fraction to achieve the same effect. Therefore, the im-
pact of redistribution and repopulation can be neglected as
the high doses will most likely cause cell cycle arrest [10]ral Ltd. This is an Open Access article distributed under the terms of the Creative
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until after about four weeks of conventional radiother-
apy [11]. Furthermore, due to the high dose rates of to-
day’s modern accelerators, repair during delivery will
also be negligible [12].
Particular attention might be required for the hypoxic
cells that are more likely to survive irradiation due to
their increased radioresistance compared to well-oxygenated
cells [13]. For conventional fractionation, reoxygenation of
hypoxic tumour cells during therapy is considered a cru-
cial process as some of the hypoxic cells are assumed to
become oxic between fractions and thus radiosensitized at
the next fraction [14,15]. Although no improvement in the
global oxygenation status through tumour shrinkage could
be expected during a short SBRT treatment course [13],
experimentally observed inter-fraction local changes in
oxygenation might benefit the treatment outcome [16].
The reduced possibility of these local changes implied by a
considerably reduced number of fractions might however
compromise the treatment outcome for patients with hyp-
oxic tumours. The oxygenation, together with the related
radiosensitivity of a tissue, should thus be considered in
evaluating the impact of extreme hypofractionation. Pre-
vious studies on this topic by Ruggieri et al. [17] and
Carlson et al. [18] led to seemingly conflicting conclusions
on how SBRT-like treatment schemes impact upon the
treatment outcome in hypoxic tumours. The present study
adds to the previous work and aims to bring further argu-
ments that may clarify the impact of hypoxia on tumour
control probability (TCP) when the dose is delivered in
very few, large fractions.Method and materials
Calculation of surviving fraction
The study was performed on voxelized three-dimensional
models simulating tumours with a diameter of 20 mm
and heterogeneous oxygenations as previously described
by Dasu et al. (2003, 2005) and Toma-Dasu et al. (2009)
[19-21]. Cell response to the treatment was calculated
using two different cell survival models, the linear-
quadratic (LQ) model [22] and the universal survival
curve (USC) model [23]. There is an on-going debate
on whether the well-established LQ model overestimates
the cell-kill for the high doses per fraction typically
employed in SBRT [24]. The universal survival curve
model, which is an empirical joining of the LQ model at
low doses and the single-hit multi-target (SHMT) model
at higher doses causing an exponential fall-off in survival
as opposed to the continuously bending LQ-curve, has
been proposed as an alternative. Therefore, to compare
the radiobiological impact of the different fractionation
schemes, both the LQ and USC approaches were consid-
ered. Using the LQ model the surviving fraction SF in afully oxygenated cell population following irradiation with
dose d is given by:
SF ¼ exp −α⋅d−β⋅d2  ð1aÞ
where α and β are the radiosensitivity parameters for oxic
conditions. The values of α and β used in all calculations
were 0.33 Gy−1 and 0.038 Gy−2 respectively (α/β = 8.6 Gy),
in accordance with the values reported by Park et al.
(2008) for NSCLC.
If the universal survival curve model is applied, the














where Dq is the dose at which the tangent of the final
slope D0 of the survival curve intercepts the horizontal
axis at 100% survival and DT is the threshold dose at
which the LQ model transitions into the SHMT model.
Values of D0, Dq and DT for NSCLC were 1.25 Gy, 1.8 Gy
and 6.2 Gy respectively [23].
As a result of the spatially varying oxygenation in the
tumour, the radiosensitivity distribution will be non-
homogeneous, causing a spatial variation in the effect-
iveness of the delivered dose. To account for the relative
increase in the effect of ionizing radiation in the presence
of oxygen [13,20], the survival models were modified to
include oxygen modifying factors (OMFs) dependent on
the local oxygen tension (pO2) [20]:
OMF pO2ð Þ ¼ OMFmax⋅ k þ pO2k þ OMFmax⋅pO2 ð2Þ
where OMFmax is the maximum relative resistance
achieved in the absence of oxygen corresponding to an
oxygen enhancement ratio (OER) of 3 and k is a reaction
constant around 2.5-3 mmHg [25]. A value of k =
2.5 mmHg was used in the current simulations.
Thus, at voxel level, the surviving fraction of cells with
a given sensitivity depending on the pO2 using the LQ
model was calculated as [26]:






Similarly, the survival under various oxygenation con-
ditions given by the universal survival curve model was
calculated as:
SF d;pO2ð Þ ¼
exp −
α
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The three-dimensional tumour oxygenation was modelled
based on biologically relevant inter-vessel distance (IVD)
distributions derived from the experimental work by
Konerding et al. (1999) [27]. By defining well-oxygenated
and hypoxic regions and assigning IVD distributions withFigure 1 Simulated tumours and their oxygenation. Two-dimensional p
pO2-histograms of the oxygen tension values for the whole (3D) tumours.
HF ≈ 64%, ii) Oxic tumour with an overall HF < 1%.different average values to these regions, in silico tumours
with different levels of hypoxic fraction (HF) were con-
structed based on the diffusion and consumption of oxy-
gen. Two different oxygen distributions were considered
for the 20 mm tumour in this study: a 13 mm hypoxic
core resulting in an overall hypoxic fraction less thanO2-maps of cross-sections through the simulated tumours and the
i) Hypoxic tumour with a 13 mm hypoxic core, overall HF ≈ 20%, core
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within the core) and an oxic tumour with less than 1%
hypoxia heterogeneously distributed. Examples of cross-
sections through these tumours and the corresponding
oxygen partial pressure histograms are shown in Figure 1.
Acute hypoxia is associated with local changes in perfu-
sion, which might take place between two consecutive
SBRT fractions [16]. In order to investigate the impact of
the resulting local oxygenation changes (LOC) on tumour
control, the values of the oxygen tension were randomly
locally redistributed at each fraction by randomly closing a
fraction of the simulated vessels. For comparison, the case
of static oxygenation was also investigated, by keeping the
oxygen distribution the same in all fractions. No substan-
tial improvement of overall tumour oxygenation associ-
ated with the slow reoxygenation of chronically hypoxic
regions was simulated, because of the short overall treat-
ment time in the SBRT treatment schedules considered
for this study [13].
Dose distribution and simulation of treatment
For comparison with clinical data the irradiation of the







Hof et al. 2007 [3]
(Germany)
26 Gy × 1 26 Isocenter 74
65.
37.
Fritz et al. 2008 [4]
(Germany)
30 Gy × 1 30 Isocenter 66%
Zimmermann et al. 2005
[5](Germany 65% isodose)
12.5 Gy × 3 37.5 60% 80% a
Baumann et al. 2009 [6]
(Sweden)
15 Gy × 3 45 67% 86%
2
Olsen et al. 2011 [7] (USA,
The Netherlands)
18 Gy × 3 54 80% 92/
85/6
Haasbeek et al. 2010 [8]
(The Netherlands)
20 Gy × 3 60 80% 85.7%
at 2 y
Takeda et al. 2009 [9]
(Canada)
10 Gy × 5 50 80% 90/
(S
Haasbeek et al. 2010 [8]
(The Netherlands)
12 Gy × 5 60 80% 85.7%
at 2 y
Haasbeek et al. 2010 [8]
(The Netherlands)
7.5 Gy × 8 60 80% 85.7%
at 2 y
aBased on doses 19–30 Gy to isocenter: 19 Gy (1 patient), 22 Gy (2), 24 Gy (7), 26 G
bPatients receiving 26–30 Gy.
cDose range 24–40 Gy, 69% was given 37.5 Gy, (2 patients had doses prescribed to
dDoses prescribed to 60-90% isodose (median 84%), overall survival expressed as o
eBased on 60 Gy total doses given in 3, 5 and 8 fractions: 3 × 20 Gy (33%), 5 × 12 G
N/A = Not Applicable.(Figure 1i) was simulated using fractionated schedules cur-
rently employed in the clinic for the SBRT treatment of
NSCLC [1-9] together with clinical prescription coverage
of the planning target volume (PTV). The explicit number
of fractions and the corresponding dose per fraction as
well as the dose prescription planning details are given in
Table 1. The diameter of the PTV was assumed to be
40 mm, corresponding to a clinical target volume (CTV)
of 20 mm with an additional 10 mm margin. Using a clin-
ically relevant dose distribution (Figure 2) the prescription
details of the reported treatment schemes given in Table 1
were fulfilled in terms of dose escalation, dose to the PTV
periphery and maximum dose.
In addition to the fractionation schemes clinically
used, schedules in which the treatment is delivered in
one, three or five fractions were employed for the mod-
elled tumour types (Figure 1). For both cases, the clin-
ically relevant dose distribution illustrated in Figure 2
was used with the fractional dose prescribed to the
69% isodose encompassing the PTV for the two tu-
mour types considered. Prescription to the 69% isodose
was chosen as representative of the current SBRT prac-
tice [1-9].d calculated TCP for the 20% hypoxic tumour (Figure 1i)
Treatment outcome TCP for LQ (USC)
erall survival Local control No LOC LOC
.5% at 1 yeara,
4% at 2 yearsa,
4% at 3 yearsa
100% at 1 yearb, 72%
at ≥ 2 yearsb
0% (0%) N/A
at 2 years, 53%
at 3 years
81% at 3 years 0% (0%) N/A
t 1 yearc, 75% at
2 yearsc
100% at 1 yearc, 87%
at 2 yearsc
7% (4%) 99% (98%)
at 1 year, 65% at
years, 60% at
3 years
92% at 3 years 56% (44%) 100% (99%)
81% at 1 yeard,
1% at 2 yearsd
99% at 1 yeard, 91%
at 2 yearsd
62% (50%) 100% (100%)
at 1 yeare, 54%
earse, 45.1% at 3
yearse
89% at 3 yearse 96% (92%) 100% (100%)
63% at 3 years,
tage 1A/1B)
93/96% at 3 years,
(Stage 1A/1B)
0% (0%) 98% (98%)
at 1 yeare, 54%
earse, 45.1% at 3
yearse
89% at 3 yearse 29% (28%) 100% (100%)
at 1 yeare, 54%
earse, 45.1% at 3
yearse
89% at 3 yearse 0% (0%) 100% (100%)
y (14), 28 Gy (10), 30 Gy (30).
80% isodose).
perable/inoperable patients and including other dose schemes.
y (50%), 8 × 7.5 Gy (17%).
Figure 2 Dose distribution for the simulation of SBRT treatments. The clinically relevant dose distribution normalized to the maximum dose
so that the percentage dose at the PTV periphery (20 mm from the centre) is 69% and the maximum dose is 100%. The extents of the CTV and
PTV are marked with red and blue lines respectively.
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control probability (TCP) calculated with a Poisson equa-
tion. Thus, the overall TCP was calculated as:




j¼1SF di; pO2 i;j
 n o ð4Þ
where n is the number of fractions, Nvox is the total
number of voxels, Ni is the number of cells in each voxel
i and di, pO2 i,j and SF(di, pO2 i,j), is the dose, the oxygen
tension and the cell survival in voxel i at fraction j. By
randomly re-distributing the pO2-values between voxels
at each fraction, experimentally observed local variations
in oxygenation between fractions [16] were simulated
[19-21,28].
In the case of static oxygenation, when the oxygen ten-
sion of the individual voxels does not change between
fractions, the surviving fraction of each voxel remains
constant during the treatment and the equation above
reduces to:
TCP ¼ exp −
XNvox




In the current study the total number of clonogenic
cells in the tumour was set to 108.
The tumour control probability was determined for in-
creasing values of total dose D, in order to generate typ-
ical dose–response curves by fitting a logit expression
(6) to the resulting TCP data [29]:
TCP ¼ 100⋅ 1
1þ D50D
 4⋅γ ð6Þ
D50 is the total dose required for a tumour control
probability of 50% and γ is the slope of the curve at 50%
TCP, similar to the clinical fit of dose–response curves.Results
The TCP values for the 20% hypoxic tumour (Figure 1i)
calculated using the clinical dose prescription schemes are
presented in Table 1 together with the reported clinical
outcome. For single-fraction schedules, there is a large dif-
ference between the predicted TCP and the clinically ob-
served values of local control. For multifraction schemes,
a trend of better agreement between clinical outcome and
simulations assuming LOC compared to the case assum-
ing static oxygenation was observed. For most of the
schedules the choice of survival model between LQ and
USC seems to have little, if any, impact on the outcome in
terms of TCP.
Figure 3i and ii show the TCP curves obtained for the
clinically-relevant theoretical schedules of different frac-
tionations when either the linear-quadratic or the uni-
versal survival curve model was used to calculate the
surviving fraction in the hypoxic (HF ≈ 20%) and the oxic
(HF < 1%) tumours (Figures 1i and ii). In Table 2 summar-
izing the D50 values, it can be observed that the D50 in-
creases as the number of fractions is increased. However,
the increase is not as large as might have been expected
from performing a simple calculation of the corresponding
equivalent isoeffective dose using a typical biological ef-
fective dose (BED) conversion [22,30]. The impact of in-
creasing the number of fractions is more pronounced for
static oxygenation. For example in Figure 3i, the curves
representing 1, 3 and 5 fractions (labelled “no LOC, LQ”)
lead to D50 values of 31.0, 46.0 and 53.9 Gy respectively.
Assuming LOC, the 7.9 Gy difference in D50 between 3
and 5 fractions is reduced to only 0.6 Gy (35.6 Gy vs.
36.2 Gy for 3 and 5 fractions respectively). Furthermore,
the difference in D50 between one and five fractions is only
5.2 Gy, (D50 = 31.0 Gy for one fraction and 36.2 Gy for five
fractions assuming LOC).
Figure 3 TCP curves using the LQ and USC models. TCP curves for a tumour with i) 20% overall hypoxic fraction located centrally and
ii) 1% hypoxic fraction, heterogeneously distributed, with and without inter-fraction LOC calculated with the linear-quadratic model and the
universal survival curve as a function of total dose prescribed to the PTV-encompassing 69% isodose.
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USC than with the LQ model, in accordance with the pre-
dicted over-estimation of clonogenic cell killing by the LQ
model. For single fraction doses, the difference between
the LQ- and USC-curves is quite large. For three and five
fractions however, the difference between using either ofthe two models seems to be negligible, the two curves for
5 fractions being visually indistinguishable for both tumour
types assuming LOC. Noticeable in Figure 3i and ii is the
smaller range of D50 for the TCP curves obtained with
USC model (thick curves) compared to the curves ob-
tained with the LQ model (thin curves). This reflects the







1 fraction 3 fractions 5 fractions
No LOC LOC No LOC LOC No LOC LOC
< 1% LQ 14.8 N/A 22.4 21.6 26.3 25.3
USC 20.1 N/A 23.3 22.9 26.3 25.3
≈ 20% LQ 31.0 N/A 46.0 35.6 53.9 36.2
USC 39.8 N/A 46.9 36.1 53.8 36.4
N/A = Not Applicable.
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fractional doses [31].
An interesting feature of the curves in Figure 3i is that
for a given level of TCP, the single-fraction curve ob-
tained with the USC model predicts a higher total dose
than some of the curves representing three and five frac-
tions. Although this might seem counterintuitive, it is
a consequence of the way the universal survival curve
model is constructed. At doses per fraction above the
transition dose DT, the universal survival curve predicts
a difference in survival compared to the LQ model that
increases with increasing dose. For the high doses re-
quired in single-fraction treatments, the difference is
most pronounced, as reflected by the large difference in
D50 between the single-fraction TCP-curves obtained
with the LQ and USC models in Figure 3i. For a total
dose delivered in three or five fractions, the fractional
dose is much closer to the transition dose and the pre-
dicted survival is thus higher.
Discussion
Hypoxia is a common feature of solid tumours that is con-
sidered responsible for the failure of many treatment ap-
proaches [32]. It has been shown to affect non-small cell
lung cancer (NSCLC) tumours, where more than 80% of
the investigated patients had a fractional hypoxic volume
(FHV) over 20% and the median FHV was 47.6% [33].
Reoxygenation of tumours is thought to be an effective
way to increase local control and it represents one of the
radiobiological rationales for conventionally-fractionated
radiotherapy. However, the impact of inter-fraction local
oxygenation changes for extremely hypofractionated SBRT
employing high doses per fraction has not been fully in-
vestigated. SBRT treatments are usually very short and
therefore they do not allow enough time for the global re-
oxygenation that results from tumour shrinkage in longer
treatments [13]. Fluctuations of acute hypoxia on the mi-
croscale, as described by Ljungkvist et al. [16] thus remain
the main mechanism that could change tumour oxygen-
ation for extremely fractionated schedules. The outcome
of the present study suggests that inter-fraction LOC is a
process that could strongly modify the response ofhypoxic tumours, possibly explaining the current success
of SBRT in treating hypoxic tumours.
The results for the clinical multifraction schedules pre-
sented in Table 1 indicate a trend of better agreement
between local control and the calculated TCP values as-
suming LOC, as opposed to the case of static oxygen-
ation. This could indicate that local oxygenation changes
might take place between fractions in clinical SBRT pa-
tients. As no information of the oxygenation or number
of clonogenic cells is available for the tumours included
in the clinical studies, a direct comparison between cal-
culated values and the reported local control is difficult
to make. For the single fraction schemes, the difference
between the observed local control and the calculated
values of TCP is large. This could be explained by the
limited knowledge of tumour response to the high doses
delivered in single-fraction treatments. It has been hy-
pothesized that there might be processes leading to in-
creased cell death only taking place at these high doses
such as vascular damage [34]. As such effects are not in-
cluded in the present modelling, they could be one of
the reasons for the observed discrepancies.
The dose–response curves and corresponding values of
D50 (Table 2) show that a great decrease in dose per frac-
tion can be expected if LOC is assumed, the total doses
for three and five fractions being almost equally low. This
offers an interesting point of view for the issue of fraction-
ation for stereotactic treatments. While extremely hypo-
fractionated schedules may not be preferred from the
point of view of the conventional fractionations where the
focus is on the differential between tumour response and
normal tissue damage, they might provide an advantage
for stereotactic treatments that are based on the limiting
of the ‘red shell’ , the high-risk zone of normal tissues re-
ceiving therapeutic doses [35]. Thus, shorter schedules
might appeal both to patients that would have to go
through fewer treatment sessions and for the radiotherapy
departments as they will free valuable accelerator time
that could in turn be used to increase patient throughput.
Nevertheless, this would apply only if LOC take place dur-
ing the treatment, as otherwise much higher doses would
be needed to achieve the same control rates.
The simulations in the present study have been per-
formed using both the LQ model and the universal
survival curve (USC) model which is an empirical exten-
sion of the LQ model. The suitability of the LQ model
for high doses has been intensely debated in recent years
[24] focusing on the possibility of overestimating cell kill
at high doses like those used in SBRT. This has led to
the development of the universal survival curve model
which is thought to better fit the experimental data in
the high-dose range [23], although the mathematical
framework and the lack of mechanistic basis of the
model has been criticized [36]. The results of the current
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ence in terms of the calculated TCP between using ei-
ther the LQ or USC formalism is not considerable.
The present study adds to the results of two previous
studies based on the LQ formalism [17,18]. Indeed, com-
paring the results in Figure 3i and ii and Table 2, it can be
seen that tumours with increased hypoxia would require
higher radiation doses to achieve a high TCP, especially in
the absence of inter-fraction LOC, which is in agreement
with the proposal of Carlson and colleagues [18]. Ruggieri
and colleagues argued that intra-tumour simultaneous
dose-boosting is capable to counteract hypoxic radioresis-
tance [17]. This statement is not in contradiction with the
results of Carlson et al. or with the results of the present
simulations. Indeed, dose escalations towards the centre of
the tumour will increase cell kill and therefore lead to
better tumour control compared to homogeneous dose
distributions, especially if the hypoxic areas are centrally
located. However for non-gated treatments, the tumour
movement relative to the treatment beams could bring the
tumour towards the lower dose regions at the margin of
the PTV, which could in turn lead to a shift of the dose re-
sponse curve to higher doses. Nevertheless, choosing suit-
able PTV-to-CTV margins might minimize the impact of
this factor and the expected differences will be small.
Conclusion
The results of this study illustrate the interplay that could
be expected between total dose, fractionation, hypoxia, and
the dynamics of oxygenation for SBRT treatments. They
suggest that extreme hypofractionation, as low as one sin-
gle dose fraction, should be pursued with caution so that
the current success of SBRT should not be jeopardized.
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